Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

37.51
-0.2300-0.61%
Pre-market: 37.09-0.4200-1.12%06:54 EDT
Volume:1.32M
Turnover:50.29M
Market Cap:2.62B
PE:-12.53
High:39.03
Open:37.60
Low:37.00
Close:37.74
52wk High:43.25
52wk Low:20.65
Shares:69.86M
Float Shares:43.70M
Volume Ratio:0.74
T/O Rate:3.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9943
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:7.51
PE(LYR):-10.76

Loading ...

Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM

TIPRANKS
·
Jun 26

Pharvaris Shareholders Adopt Dutch Statutory Annual Accounts for Fy2025

Reuters
·
Jun 26

Pharvaris is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jun 26

Pharvaris price target raised to $46 from $41 at Morgan Stanley

TIPRANKS
·
Jun 25

Pharvaris CMO Lu Peng disposes of 300 shares worth $10,200

Reuters
·
Jun 24

Pharvaris (PHVS) Is Up 6.0% After Strong Phase 3 Oral HAE Data With Novel Endpoint Introduction

Simply Wall St.
·
Jun 19

Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Pharvaris (PHVS)

TIPRANKS
·
Jun 16

Pharvaris says Phase 3 RAPIDe-3 trial shows oral deucrictibant cuts median HAE symptom relief time to 1.28 hours

Reuters
·
Jun 15

Pharvaris publishes patient-reported outcomes presentation on clinical evidence in HAE trials

Reuters
·
Jun 12

Pharvaris announces annual shareholder meeting

Reuters
·
Jun 11

A Look At Pharvaris (PHVS) Valuation As Deucrictibant Data Advances Toward Key EAACI 2026 Catalyst

Simply Wall St.
·
Jun 07

The Bull Case For Pharvaris (PHVS) Could Change Following New Deucrictibant Phase 3 Data Disclosures

Simply Wall St.
·
May 31

Pharvaris to present Phase 3 RAPIDe-3 end-of-progression data for oral deucrictibant in hereditary angioedema at EAACI 2026

Reuters
·
May 29

Pharvaris Principal Accounting Officer Anna Nijdam disposes of common shares worth $224,207.69

Reuters
·
May 27

Pharvaris director Elisabeth Bjork disposes 10,000 common shares for $293,166

Reuters
·
May 23

Pharvaris Chief Commercial Officer Wim Souverijns sells 10,000 shares for $299,163

Reuters
·
May 20

Pharvaris price target raised to $33 from $31 at BofA

TIPRANKS
·
May 15

Pharvaris (PHVS) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 14

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pharvaris (PHVS) and Allogene Therapeutics (ALLO)

TIPRANKS
·
May 14

Stock Track | Pharvaris N.V. Soars 5.09% Intraday on Bullish Analyst Ratings

Stock Track
·
May 14